Raymond James analyst Jonathan Hughes maintained a Buy rating on Ventas (VTR – Research Report) today and set a price target of $67.00. The company’s shares closed last Thursday at $59.25, close to its 52-week high of $61.09.
According to TipRanks.com, Hughes is a 4-star analyst with an average return of 10.5% and a 64.3% success rate. Hughes covers the Financial sector, focusing on stocks such as Omega Healthcare, CareTrust REIT, and Welltower.
Currently, the analyst consensus on Ventas is a Moderate Buy with an average price target of $62.95, implying an 8.4% upside from current levels. In a report issued on March 11, BMO Capital also upgraded the stock to Buy with a $67.00 price target.
Based on Ventas’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.02 billion and GAAP net loss of $40.85 million. In comparison, last year the company earned revenue of $921 million and had a net profit of $110 million.
Based on the recent corporate insider activity of 87 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VTR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ventas, Inc. engages in the acquisition and ownership of seniors housing and healthcare properties. The company invests in seniors housing and healthcare properties through acquisitions and leases its properties to unaffiliated tenants or operate them through independent third-party managers. It operates through the following segments: Triple-Net Leased Properties, Senior Living Operations, and Office Operations. The company was founded in 1983 and is headquartered in Chicago, IL.
Read More on VTR:
- Nike (NKE) Gets a Buy Rating from Telsey Advisory
- Ayr Wellness (AYRWF) Receives a Hold from Cantor Fitzgerald
- Science Applications (SAIC) Gets a Buy Rating from Morgan Stanley
- Morgan Stanley Sticks to Their Hold Rating for Janus International Group (JBI)
- Analysts Are Bullish on These Healthcare Stocks: Ayr Wellness (AYRWF), Crinetics Pharmaceuticals (CRNX)